Novavax trial reveals 89.3% effectiveness in preventing COVID-19

Interim analysis of study shows that the NIHR-supported Novavax COVID-19 vaccine is 89.3% effective at preventing COVID-19, including effectiveness against the new variants of concern.

By NIHR Wellcome King's Clinical Research Facility at 29 Jan 2021

SIREN study finds past COVID-19 infection provides some immunity for at least five months

The first report from Public Health England's national SIREN study, supported at King's College Hospital by the King's CRF, has found that past COVD-19 infection provides 83% immunity for at least five months. However, some people may still carry the virus and transmit to other people.

By NIHR Wellcome King's Clinical Research Facility at 19 Jan 2021